Loading market dashboard
Adagene Inc.
ADAGHealthcareNASDAQCN
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company's focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology.
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 411,325 shares, a growth of 477.3% from the March 31st total of 71,244 shares. Approximately 1.1% of the shares of the stock
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients
Adagene is essentially a single-asset bet on ADG126, which is a masked anti-CTLA-4 antibody designed to improve tolerability in immuno-oncology. ADG126's upcoming AACR 2026 updates are likely the biggest near-term catalysts to look forward to this year. ADAG also has partnerships with Sanofi and Incyte that validate its pipeline to some extent. These also open the door to potential milestone and royalty payments.
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the addition of Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board (SAB).
Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation. Analyst Recommendations This is a breakdown of current
SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of 18,666,000 American depositary shares, or ADSs, each representing 1.25 ordinary shares of the Company, par value US$0.0001 per share, at the offering price of US$3.75 per ADS, representing the 30-day volume-weighted average price (“VWAP”).
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases
Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10 mg/kg dose cohorts
In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months 4% overall discontinuation rate, no dose limiting toxicities, and no Grade 4 or 5 treatment-related adverse events (TRAEs) across 67 patients in all dose cohorts supports improved tolerability profile of muzastotug Randomized Phase 2 trial enrollment ahead of plan, with potential updates in 2026 and results expected in 1H 2027; registration trial expected to begin once optimal dose regimen has been established Cash and cash equivalents of $74.5 million as of December 31, 2025, plus proceeds raised from the ATM Offering in 2026 year-to-date, anticipated to provide cash runway into early 2028 SAN DIEGO, Calif. and SUZHOU, China, April 01, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel anti-body-based therapies, today reported financial results for the full year 2025 and provided corporate updates.
Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 74,016 shares, a growth of 44.6% from the February 26th total of 51,190 shares. Approximately 0.2% of the company's shares are short
SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year's AACR Meeting, taking place April 17-22 in San Diego, CA.
